Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
best practice onkologie
Erschienen in: best practice onkologie 1-2/2023

30.01.2023 | Weichteilsarkome | CME-Topic

Lokalisierte Weichgewebesarkome

verfasst von: PD Dr. med. Lars Erik Podleska, Sebastian Bauer, Christoph Pöttgen, Arne Streitbürger, Jendrik Hardes, Georg Täger

Erschienen in: best practice onkologie | Ausgabe 1-2/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Weichgewebesarkome sind selten. Die Symptome sind unspezifisch, die Tumoren treten an unterschiedlichsten Lokalisationen auf. Wegen des hohen Verteilungsgrads dieser Tumoren auf unterschiedliche Akteure des Gesundheitswesens ist das klinische Management von Weichgewebesarkomen problembehaftet. Die kontrastmittelverstärkte Magnetresonanztomographie (MRT) ist unverzichtbar zur Diagnostik. Die Weichenstellung der Therapie erfolgt durch eine korrekt durchgeführte und im Referenzzentren analysierte Biopsie. Grundpfeiler der lokalen Tumorbehandlung ist die Abwägung im prätherapeutischen Tumorboard. Grundzüge von Epidemiologie, Diagnostik, Verlaufskontrolle und v. a. der Entscheidungsfindung, basierend auf der Biopsie, werden dargestellt. Der multimodale Behandlungsansatz wird unter Hinweis auf die einschlägige und aktuelle Literatur skizziert. Die fachübergreifende S3-Leitlinie Weichgewebesarkome ist dabei ein wichtiges Instrument zur Steigerung von Behandlungsqualität und Patientensicherheit.
Literatur
1.
Montgomery C, Park KJ, Gardner JM et al (2019) Post-traumatic sarcomas: do they exist? Int J Surg Pathol 27:722–728CrossRef
2.
Davidson T, Westbury G, Harmer CL (1986) Radiation-induced soft-tissue sarcoma. Br J Surg 73:308–309CrossRef
3.
Virtanen A, Pukkala E, Auvinen A (2006) Incidence of bone and soft tissue sarcoma after radiotherapy: a cohort study of 295,712 Finnish cancer patients. Int J Cancer 118:1017–1021CrossRef
4.
AACR Project GENIE Consortium (2017) AACR project GENIE: powering precision medicine through an international consortium. Cancer Discov 7:818–831CrossRef
5.
Maccarthy A, Bayne AM, Brownbill PA et al (2013) Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004. Br J Cancer 108:2455–2463CrossRef
6.
Jouenne F, Chauvot De Beauchene I, Bollaert E et al (2017) Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma. J Med Genet 54:607–612CrossRef
7.
Nandra R et al (2015) If your lump is bigger than a golf ball and growing, think Sarcoma. Eur J Surg Oncol 41(10):1400–1405CrossRef
8.
9.
Cairncross L, Snow HA, Strauss DC et al (2019) Diagnostic performance of MRI and histology in assessment of deep lipomatous tumours. Br J Surg 106:1794–1799CrossRef
10.
Subhawong TK, Wilky BA (2015) Value added: functional MR imaging in management of bone and soft tissue sarcomas. Curr Opin Oncol 27:323–331CrossRef
11.
Crombe A, Alberti N, Stoeckle E et al (2016) Soft tissue masses with myxoid stroma: can conventional magnetic resonance imaging differentiate benign from malignant tumors? Eur J Radiol 85:1875–1882CrossRef
12.
Erfanian Y, Grueneisen J, Kirchner J et al (2017) Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial. Eur J Nucl Med Mol Imaging 44(11):1823–1831CrossRef
13.
Fuglo HM, Jorgensen SM, Loft A et al (2012) The diagnostic and prognostic value of (1)(8)F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging 39:1416–1424CrossRef
14.
Sambri A, Bianchi G, Longhi A et al (2019) The role of 18F-FDG PET/CT in soft tissue sarcoma. Nucl Med Commun 40:626–631CrossRef
15.
Casali PG, Abecassis N, Aro HT et al (2018) Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv51–iv67CrossRef
16.
Umer HM, Umer M, Qadir I et al (2013) Impact of unplanned excision on prognosis of patients with extremity soft tissue sarcoma. Sarcoma 2013:498604CrossRef
17.
Grabellus F, Podleska LE, Sheu SY et al (2012) Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. Eur J Surg Oncol 39:61–67CrossRef
18.
Gronchi A, Miah AB, Dei Tos AP et al (2021) Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up(). Ann Oncol 32:1348–1365CrossRef
19.
Fleshman R, Mayerson J, Wakely PE Jr. (2007) Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases. Cancer 111:491–498CrossRef
20.
Agaimy A (2014) Value of core needle biopsy in preoperative diagnostics of soft tissue tumors: possibilities and limitations. Pathologe 35(2):189–197CrossRef
21.
Traina F, Errani C, Toscano A et al (2015) Current concepts in the biopsy of musculoskeletal tumors. J Bone Joint Surg Am 97:e7CrossRef
22.
Young R, Snow H, Hendry S et al (2020) Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single-centre study. ANZ J Surg 90:497–502CrossRef
23.
Al-Ibraheemi A, Folpe AL (2016) Voluntary second opinions in pediatric bone and soft tissue pathology: a retrospective review of 1601 cases from a single mesenchymal tumor consultation service. Int J Surg Pathol 24:685–691CrossRef
24.
Pisters PW, Leung DH, Woodruff J et al (1996) Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14:1679–1689CrossRef
25.
Callegaro D, Miceli R, Bonvalot S et al (2016) Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol 17:671–680CrossRef
26.
Gronchi A, Miceli R, Shurell E et al (2013) Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol 31:1649–1655CrossRef
27.
Berardi R, Morgese F, Rinaldi S et al (2020) Benefits and limitations of a multidisciplinary approach in cancer patient management. Cancer Manag Res 12:9363–9374CrossRef
28.
Blay JY, Soibinet P, Penel N et al (2017) Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol 28:2852–2859CrossRef
29.
Eichler M, Andreou D, Golcher H et al (2021) Utilization of interdisciplinary tumor boards for sarcoma care in Germany: results from the PROsa study. Oncol Res Treat 44:301–312CrossRef
30.
Lohsträter A, Germann S, Kohlmann T (2010) Möglichkeiten der Heilverfahrenssteuerung. Trauma Berufskrankh 12:199–207CrossRef
31.
Grunewald TG, Alonso M, Avnet S et al (2020) Sarcoma treatment in the era of molecular medicine. EMBO Mol Med 12:e11131CrossRef
32.
Abendroth A, Bauer S (2013) Adjuvant chemotherapy for soft tissue sarcoma? a clear no–well–yes–ish. Dtsch Med Wochenschr 138:2107–2110
33.
Collin C, Godbold J, Hajdu S et al (1987) Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 5:601–612CrossRef
34.
Stojadinovic A, Leung DH, Hoos A et al (2002) Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 235:424–434CrossRef
35.
Willeumier JJ, Rueten-Budde AJ, Jeys LM et al (2017) Individualised risk assessment for local recurrence and distant metastases in a retrospective transatlantic cohort of 687 patients with high-grade soft tissue sarcomas of the extremities: a multistate model. BMJ Open 7:e12930CrossRef
36.
Lahat G, Tuvin D, Wei C et al (2008) New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol 15:2739–2748CrossRef
37.
Hagenmaier HSF, van Beeck AGK, Haas RL et al (2021) The influence of personalised sarcoma care (PERSARC) prediction modelling on clinical decision making in a multidisciplinary setting. Sarcoma 2021:8851354CrossRef
38.
Rueten-Budde AJ, van Praag VM, Studygroup P et al (2018) Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surg Oncol 27:695–701CrossRef
39.
Trovik CS, Bauer HC, Alvegard TA et al (2000) Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian sarcoma group register. Eur J Cancer 36:710–716CrossRef
40.
Enneking WF, Kagan A (1975) “Skip” metastases in osteosarcoma. Cancer 36:2192–2205CrossRef
41.
Enneking WF, Spanier SS, Goodman MA (1980) A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980(153):106–120
42.
Grabellus F, Kraft C, Sheu SY et al (2009) Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol 16:676–686CrossRef
43.
Jebsen NL, Engellau J, Engstrom K et al (2013) Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. Int J Radiat Oncol Biol Phys 86:949–955CrossRef
44.
Harati K, Goertz O, Pieper A et al (2017) Soft tissue sarcomas of the extremities: surgical margins can be close as long as the resected tumor has no ink on it. Oncologist 22:1400–1410CrossRef
45.
Lin PP, Pino ED, Normand AN et al (2007) Periosteal margin in soft-tissue sarcoma. Cancer 109:598–602CrossRef
46.
Chang HR, Gaynor J, Tan C et al (1990) Multifactorial analysis of survival in primary extremity liposarcoma. World J Surg 14:610–618CrossRef
47.
Chandrasekar CR, Wafa H, Grimer RJ et al (2008) The effect of an unplanned excision of a soft-tissue sarcoma on prognosis. J Bone Joint Surg Br 90:203–208CrossRef
48.
Alektiar KM, Velasco J, Zelefsky MJ et al (2000) Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 48:1051–1058CrossRef
49.
Alamanda VK, Delisca GO, Mathis SL et al (2013) The financial burden of reexcising incompletely excised soft tissue sarcomas: a cost analysis. Ann Surg Oncol 20:2808–2814CrossRef
50.
Stotter A, Fallowfield M, Mott A et al (1990) Role of compartmental resection for soft tissue sarcoma of the limb and limb girdle. Br J Surg 77:88–92CrossRef
51.
Pollock RE (1994) Limb-sparing therapy for soft tissue sarcomas. Curr Opin Gen Surg: 224–229
52.
53.
Rosenberg SA, Tepper J, Glatstein E et al (1982) The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 196:305–315CrossRef
54.
Eggermont AM, Schraffordt Koops H, Klausner JM et al (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224:756–764 (discussion 764–755)CrossRef
55.
Albertsmeier M, Rauch A, Roeder F et al (2018) External beam radiation therapy for resectable soft tissue sarcoma: a systematic review and meta-analysis. Ann Surg Oncol 25:754–767CrossRef
56.
Gingrich AA, Bateni SB, Monjazeb AM et al (2017) Neoadjuvant radiotherapy is associated with R0 resection and improved survival for patients with extremity soft tissue sarcoma undergoing surgery: a national cancer database analysis. Ann Surg Oncol 24:3252–3263CrossRef
57.
O’sullivan B, Davis AM, Turcotte R et al (2002) Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359:2235–2241CrossRef
58.
Dickson MA, Schwartz GK, Keohan ML et al (2016) Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2:937–940CrossRef
59.
Martin-Tellez KS, van Houdt WJ, van Coevorden F et al (2020) Isolated limb perfusion for soft tissue sarcoma: current practices and future directions. A survey of experts and a review of literature. Cancer Treat Rev 88:102058CrossRef
60.
Keung EZ, Tsai JW, Ali AM et al (2018) Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. OncoImmunology 7:e1385689CrossRef
61.
Orth M, Lauber K, Niyazi M et al (2014) Current concepts in clinical radiation oncology. Radiat Environ Biophys 53:1–29CrossRef
62.
Taeger G, Grabellus F, Podleska LE et al (2008) Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 24:193–203CrossRef
63.
Beane JD, Yang JC, White D et al (2014) Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol 21:2484–2489CrossRef
64.
Eilber FC, Brennan MF, Riedel E et al (2005) Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas. Ann Surg Oncol 12:228–236CrossRef
65.
Gronchi A, Casali PG, Mariani L et al (2005) Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 23:96–104CrossRef
66.
O’donnell PW, Griffin AM, Eward WC et al (2014) The effect of the setting of a positive surgical margin in soft tissue sarcoma. Cancer 120:2866–2875CrossRef
67.
Arndt CA, Crist WM (1999) Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341:342–352CrossRef
68.
Pasquali S, Pizzamiglio S, Touati N et al (2019) The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer 109:51–60CrossRef
69.
Pasquali S, Colombo C, Pizzamiglio S et al (2018) High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial. Eur J Cancer 93:28–36CrossRef
70.
Cocco E, Scaltriti M, Drilon A (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731–747CrossRef
71.
Dieckmann N, Schildhaus HU, Bauer S (2021) Tropomyosin receptor kinases in sarcomas—of joy and despair. Curr Opin Oncol 33:336–344CrossRef
72.
Bissler JJ, Kingswood JC, Radzikowska E et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817–824CrossRef
73.
Bauer S, Demetri GD, Halilovic E et al (2021) Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. Br J Cancer 125:687–698CrossRef
74.
Paoluzzi L, Cacavio A, Ghesani M et al (2016) Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res 6:24CrossRef
75.
Tawbi HA, Burgess M, Bolejack V et al (2017) Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 18:1493–1501CrossRef
76.
Hamacher R, Kampfe D, Reuter-Jessen K et al (2018) Dramatic response of a PD-L1-positive advanced angiosarcoma of the scalp to pembrolizumab. JCO Precis Oncol 2:1–7
77.
Vanhersecke L, Brunet M, Guegan JP et al (2021) Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer 2:794–802CrossRef
Metadaten
Titel
Lokalisierte Weichgewebesarkome
verfasst von
PD Dr. med. Lars Erik Podleska
Sebastian Bauer
Christoph Pöttgen
Arne Streitbürger
Jendrik Hardes
Georg Täger
Publikationsdatum
30.01.2023
Verlag
Springer Medizin
Erschienen in
best practice onkologie / Ausgabe 1-2/2023
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI
https://doi.org/10.1007/s11654-022-00458-5

Weitere Artikel der Ausgabe 1-2/2023

best practice onkologie 1-2/2023 Zur Ausgabe

Praxis- und Klinikmanagement

Ein Viertel der Ärzte denkt über einen Berufswechsel nach

Interview

Wie kann eine patientenzentrierte Onkologie gelingen?

Kongresse – wichtig zu wissen

Wichtige Studien vom ASH 2022

onko-aktuell

onko-aktuell

Topic

Digitalisierung in der Dermatoonkologie: künstliche Intelligenz zur Diagnostik

Editorial

Ambulantisierung der Krankenhäuser

Weitere Lesetipps

ANZEIGE

Dexpanthenol verstärkt die positiven Effekte der LASH-Methode

Neoadjuvante Bestrahlung bei Rektum-Ca. oft überflüssig

"Adipositas ist eine Erkrankung, die jeden betreffen kann"

ANZEIGE

Neue Konzepte beim Handekzem

ANZEIGE

Weißer Hautkrebs verursacht mehr Tote als das Melanom

Welcher Laser für welche Narbe?

Bildnachweise